---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-086190"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2026-08-06T20:40:40+00:00"
generated_at: "2026-08-06T20:42:47.572287+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada reports Q2 net loss $12.9M; cash $217.7M; NDV-01 IND on track for YE26

## Summary
- Net loss of $12.9M ($0.11/share) vs $9.9M loss in Q2 2025; R&D expense rose to $8.4M from $2.8M.
- Cash, equivalents, and short-term investments of $217.7M as of June 30, 2026, expected to fund operations through 2029.
- NDV-01 IND filing expected by year-end 2026; Phase 3 RESCUE program initiation upon IND clearance.
- Sepranolone IND filing expected by year-end 2026; Phase 2 proof-of-concept in Prader-Willi Syndrome upon clearance.
- Appointed Bipin Dalmia as Chief Business Officer; added to Russell 2000 and 3000 indexes in June 2026.

## SEC filing metadata
- accession: 0001213900-26-086190
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2026-08-06T20:40:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/0001213900-26-086190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea0300993-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-086190
- JSON: https://secwatch.observer/filing/0001213900-26-086190.json
- Plain text: https://secwatch.observer/filing/0001213900-26-086190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.